trial

Treating Drug-Resistant Childhood Schizophrenia

NCTId NCT00048828
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 41 (actual)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2006-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
41 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2001-10
Primary completion
2006-06
Eligibility
ALL · 10 Years · 18 Years

Interventions & indications

Drugs
OlanzapineClozapine

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Christoph U. Correll, MDPrincipal Investigator

Sites

3 total
Dix Hills, United StatesGlen Oaks, United StatesThe Bronx, United States

Facts & assertions

4 sourced
Enrollment
41
Phase
PHASE4
Primary Completion Date
2006-06
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Clozapine
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Christoph U. Correll, MD
person